{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:04:15Z","timestamp":1791515055331,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009068","name":"Universit\u00e4t Bern","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009068","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>While acquisition of images in [<jats:sup>68<\/jats:sup>\u00a0Ga]Ga-PSMA-11 following longer uptake times can improve lesion uptake and contrast, resultant imaging quality and count statistics are limited by the isotope\u2019s half-life (68\u00a0min). Here, we present a series of cases demonstrating that when performed using a long axial field-of-view (LAFOV) PET\/CT system, late imaging is feasible and can even provide improved image quality compared to regular acquisitions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective case series, we report our initial experiences with 10 patients who underwent standard imaging at 1\u00a0h p.i. following administration of 192\u2009\u00b1\u200936\u00a0MBq [<jats:sup>68<\/jats:sup>\u00a0Ga]Ga-PSMA-11 with additional late imaging performed at 4\u00a0h p.i. Images were acquired in a single bed position for 6\u00a0min at 1\u00a0h p.i. and 16\u00a0min p.i. at 4\u00a0h p.i. using a LAFOV scanner (106\u00a0cm axial FOV). Two experienced nuclear medicine physicians reviewed all scans in consensus and evaluated overall image quality (5-point Likert scale), lesion uptake in terms of standardised uptake values (SUV), tumour to background ratio (TBR) and target-lesion signal to background noise (SNR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Subjective image quality as rated on a 5-point Likert scale was only modestly lower for late acquisitions (4.2\/5 at 4\u00a0h p.i.; 5\/5 1\u00a0h p.i.), TBR was significantly improved (4\u00a0h: 3.41 vs 1\u00a0h: 1.93, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and SNR was improved with borderline significance (4\u00a0h: 33.02 vs 1\u00a0h: 24.80, <jats:italic>p<\/jats:italic>\u2009=\u20090.062) at later imaging. Images were obtained with total acquisition times comparable to routine examinations on standard axial FOV scanners.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Late acquisition in tandem with a LAFOV PET\/CT resulted in improvements in TBR and SNR and was associated with only modest impairment in subjective visual imaging quality. These data show that later acquisition times for [<jats:sup>68<\/jats:sup>\u00a0Ga]Ga-PSMA-11 may be preferable when performed on LAFOV systems.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-021-05438-5","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T18:03:01Z","timestamp":1624298581000},"page":"4456-4462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET\/CT using a long axial field-of-view PET\/CT scanner for the diagnosis of recurrent prostate cancer\u2014first clinical experiences"],"prefix":"10.1007","volume":"48","author":[{"given":"Ian","family":"Alberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Prenosil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Mingels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Peter","family":"Bohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Viscione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Sari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afshar-Oromieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"5438_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2967\/jnumed.116.184028","volume":"59","author":"SR Cherry","year":"2018","unstructured":"Cherry SR, Jones T, Karp JS, Qi J, Moses WW, Badawi RD. Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care. J Nucl Med Off Publ Soc Nucl Med. 2018;59:3\u201312. https:\/\/doi.org\/10.2967\/jnumed.116.184028.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"5438_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2967\/jnumed.119.226498","volume":"60","author":"RD Badawi","year":"2019","unstructured":"Badawi RD, Shi H, Hu P, Chen S, Xu T, Price PM, et al. First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med Off Publ Soc Nucl Med. 2019;60:299\u2013303. https:\/\/doi.org\/10.2967\/jnumed.119.226498.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"5438_CR3","doi-asserted-by":"publisher","unstructured":"Spencer BA, Berg E, Schmall JP, Omidvari N, Leung EK, Abdelhafez YG, et al. Performance evaluation of the uEXPLORER total-body PET\/CT scanner based on NEMA NU 2\u20132018 with additional tests to characterize long axial field-of-view PET scanners. J Nucl Med. 2020:jnumed.120.250597. https:\/\/doi.org\/10.2967\/jnumed.120.250597.","DOI":"10.2967\/jnumed.120.250597"},{"key":"5438_CR4","unstructured":"Siegel S, Aykac M, Bal H, Bendriem B, Bharkhada D, Cabello J, et al. Preliminary performance of a prototype, one-meter long PET tomograph. IEEE NSS-MIC. Boston, MA: IEEE; 2020."},{"key":"5438_CR5","doi-asserted-by":"crossref","unstructured":"Prenosil GA, Sari H, F\u00fcrstner M, et al. Performance characteristics of the biopgraph vision quadra PET\/CT system with long axial field of view using the NEMA NU 2-2018 Standard. J Nucl Med; 2021. (in press).","DOI":"10.1055\/s-0041-1726744"},{"key":"5438_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05282-7","author":"I Alberts","year":"2021","unstructured":"Alberts I, H\u00fcnermund J-N, Prenosil G, Mingels C, Bohn KP, Viscione M, et al. Clinical performance of long axial field of view PET\/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET\/CT. European J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05282-7.","journal-title":"European J Nucl Med Mol Imaging"},{"key":"5438_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486\u201395. https:\/\/doi.org\/10.1007\/s00259-012-2298-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5438_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05189-3","author":"A Afshar-Oromieh","year":"2021","unstructured":"Afshar-Oromieh A, da Cunha ML, Wagner J, Haberkorn U, Debus N, Weber W, et al. Performance of [68Ga]Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer after prostatectomy\u2014a multi-centre evaluation of 2533 patients. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05189-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5438_CR9","doi-asserted-by":"publisher","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. (68)Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014\u201324. https:\/\/doi.org\/10.1007\/s00259-017-3670-z.","DOI":"10.1007\/s00259-017-3670-z"},{"key":"5438_CR10","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00259-016-3419-0","volume":"43","author":"A Afshar-Oromieh","year":"2016","unstructured":"Afshar-Oromieh A, Hetzheim H, Kubler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611\u201320. https:\/\/doi.org\/10.1007\/s00259-016-3419-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5438_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00259-019-04545-8","volume":"47","author":"I Alberts","year":"2020","unstructured":"Alberts I, Sachpekidis C, Gourni E, Boxler S, Gross T, Thalmann G, et al. Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2020;47:160\u20137. https:\/\/doi.org\/10.1007\/s00259-019-04545-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5438_CR12","doi-asserted-by":"crossref","unstructured":"Schmuck S, Mamach M, Wilke F, von Klot CA, Henkenberens C, Thackeray JT, et al. Multiple time-point 68Ga-PSMA I&T PET\/CT for characterization of primary prostate cancer: value of early dynamic and delayed imaging. Clin Nucl Med. 2017;42.","DOI":"10.1097\/RLU.0000000000001589"},{"key":"5438_CR13","doi-asserted-by":"publisher","unstructured":"Alberts I, Huenermund JN, Sachpekidis C, Zacho HD, Mingels C, Dijkstra L, et al. Combination of forced diuresis with additional late imaging in 68Ga-PSMA-11 PET\/CT\u2013effects on lesion visibility and radiotracer uptake. J Nucl Med. 2021:jnumed.120.257741. https:\/\/doi.org\/10.2967\/jnumed.120.257741.","DOI":"10.2967\/jnumed.120.257741"},{"key":"5438_CR14","doi-asserted-by":"publisher","unstructured":"Hoffmann MA, Buchholz H-G, Wieler HJ, Rosar F, Miederer M, Fischer N, et al. Dual-time point [68Ga]Ga-PSMA-11 PET\/CT hybrid imaging for staging and restaging of prostate cancer. Cancers. 2020;12. doi:https:\/\/doi.org\/10.3390\/cancers12102788.","DOI":"10.3390\/cancers12102788"},{"key":"5438_CR15","doi-asserted-by":"publisher","first-page":"750","DOI":"10.2967\/jnumed.116.183483","volume":"58","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, Sattler LP, Mier W, Hadaschik BA, Debus J, Holland-Letz T, et al. The clinical impact of additional late PET\/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med. 2017;58:750. https:\/\/doi.org\/10.2967\/jnumed.116.183483.","journal-title":"J Nucl Med"},{"key":"5438_CR16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00259-019-04552-9","volume":"47","author":"I Alberts","year":"2020","unstructured":"Alberts I, Sachpekidis C, Dijkstra L, Prenosil G, Gourni E, Boxler S, et al. The role of additional late PSMA-ligand PET\/CT in the differentiation between lymph node metastases and ganglia. Eur J Nucl Med Mol Imaging. 2020;47:642\u201351. https:\/\/doi.org\/10.1007\/s00259-019-04552-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5438_CR17","doi-asserted-by":"publisher","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA-RADS Version 1.0: a step towards standardizing the interpretation and reporting of PSMA\u2013targeted PET imaging studies. Eur Urol. 2018;73:485\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2017.10.027.","DOI":"10.1016\/j.eururo.2017.10.027"},{"key":"5438_CR18","doi-asserted-by":"crossref","unstructured":"Mingels C, Sachpekidis C, Bohn KP, H\u00fcnermund J-N, Schepers R, Fech V, et al. The influence of colour scale in lesion detection and patient-based sensitivity in [68Ga]Ga-PSMA-PET\/CT. Nuclear Medicine Communications. 2021;Publish Ahead of Print.","DOI":"10.1055\/s-0041-1726844"},{"key":"5438_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13550-016-0177-8","volume":"6","author":"A Sher","year":"2016","unstructured":"Sher A, Lacoeuille F, Fosse P, Vervueren L, Cahouet-Vannier A, Dabli D, et al. For avid glucose tumors, the SUV peak is the most reliable parameter for [(18)F]FDG-PET\/CT quantification, regardless of acquisition time. EJNMMI Res. 2016;6:21. https:\/\/doi.org\/10.1186\/s13550-016-0177-8.","journal-title":"EJNMMI Res"},{"key":"5438_CR20","doi-asserted-by":"publisher","unstructured":"Prenosil GA, Weitzel T, Furstner M, Hentschel M, Krause T, Cumming P, et al. Towards guidelines to harmonize textural features in PET: Haralick textural features vary with image noise, but exposure-invariant domains enable comparable PET radiomics. PLoS ONE. 2020;15. https:\/\/doi.org\/10.1371\/journal.pone.0229560.","DOI":"10.1371\/journal.pone.0229560"},{"key":"5438_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40644-016-0086-0","volume":"16","author":"J Yan","year":"2016","unstructured":"Yan J, Schaefferkoetter J, Conti M, Townsend D. A method to assess image quality for low-dose PET: analysis of SNR, CNR, bias and image noise. Cancer Imaging. 2016;16:26. https:\/\/doi.org\/10.1186\/s40644-016-0086-0.","journal-title":"Cancer Imaging"},{"key":"5438_CR22","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00259-019-04548-5","volume":"47","author":"F Haupt","year":"2020","unstructured":"Haupt F, Dijkstra L, Alberts I, Sachpekidis C, Fech V, Boxler S, et al. 68Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer\u2014a modified protocol compared with the common protocol. Eur J Nucl Med Mol Imaging. 2020;47:624\u201331. https:\/\/doi.org\/10.1007\/s00259-019-04548-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5438_CR23","doi-asserted-by":"crossref","unstructured":"Rauscher I, Fendler WP, Hope T, Quon A, Nekolla SG, Calais J, et al. Can the injected dose be reduced in 68Ga-PSMA-11 PET\/CT maintaining high image quality for lesion detection? J Nucl Med. 2019.","DOI":"10.2967\/jnumed.119.227207"},{"key":"5438_CR24","unstructured":"https:\/\/www.siemens-healthineers.com\/molecular-imaging\/options-and-upgrades\/software-applications\/flowmotion-technology."},{"key":"5438_CR25","unstructured":"Mueller D, Fuchs A, Leshch Y, Proehl M. The shortage of approved 68Ga generators-incoming material inspection and GMP compliant use of non-approved generators. J Nucl Med. 2019;60:1059-."},{"key":"5438_CR26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388. https:\/\/doi.org\/10.1007\/s00259-016-3573-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5438_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","volume":"17","author":"Z Szabo","year":"2015","unstructured":"Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565\u201374. https:\/\/doi.org\/10.1007\/s11307-015-0850-8.","journal-title":"Mol Imaging Biol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05438-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05438-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05438-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T06:10:09Z","timestamp":1638511809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05438-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5438"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05438-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]},"assertion":[{"value":"26 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The cantonal ethics committee provided a waiver for retrospective analysis of this cohort (Req-2021\u201300141). All patients provided written informed consent for inclusion in this study. The study was performed in accordance with the declaration of Helsinki and relevant national legislation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"HS is a full-time employee of Siemens Healthcare AG, Switzerland.AR has received research support and speaker honoraria from Siemens.All other authors have no conflicts of interest to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}